RxDoctor Payments Data

David Axline, MD

Cardiovascular Disease · Naples, FLNPI 1023002003

Payments from drug & device makers

$10,848in general payments, 2019–2025

Across 129 payments — averaging $84.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$5K
  • Boston Scientific$2K
  • Edwards Lifesciences$1K
  • Medtronic$736
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$392
  • Abiomed$363
  • plus $1K from 13 others

What the payments were for

  • Travel & lodging$4,86545%
  • Food & beverage$5,98355%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$10,848 in reported general payments places this provider in the 70th percentile of 1,740 cardiovascular disease providers in Florida.

See all cardiovascular disease providers in Florida

Medicare billing

Part B allowed, 2024
$774,299
Medicare patients
4,114
Services billed
8,863

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban855$1,184,220
XareltoRivaroxaban242$335,201
EntrestoSacubitril/Valsartan135$210,587
JardianceEmpagliflozin118$129,373
Repatha SureclickEvolocumab71$85,787
Praluent PenAlirocumab50$37,576
Metoprolol Succinate980$17,338
BrilintaTicagrelor14$12,342
Dabigatran EtexilateDabigatran Etexilate Mesylate19$8,273
Ranolazine ErRanolazine66$7,531
Atorvastatin Calcium723$7,455
Ezetimibe208$6,706
Rosuvastatin Calcium391$5,332
Diltiazem 24hr Er (Cd)Diltiazem Hcl131$5,089
Flecainide Acetate74$5,067

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$56$1,184,220855 claims
Boehringer IngelheimJardiance$20$129,373118 claims
AstraZenecaBrilinta$32$12,34214 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 1,740 cardiovascular disease providers in Florida.

Other cardiovascular disease in Naples

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →